United Nations Genetic Ethics Negotiation Entity

The genetic revolution is no longer science fiction, it’s shaping the future of health, identity, and inequality. As gene editing, embryo screening, and advanced therapies evolve at fast speed, the world faces an urgent question: who gets to decide how far we go? At the United Nations Genetic Ethics Negotiation Entity, delegates will tackle the ethical, legal, and political dilemmas that define this new era.

From the $2.1 million price tag of life-saving treatments to the quiet rise of genetic privilege, the line between healing and enhancing is growing dangerously thin. As access to biotech remains concentrated in wealthier nations and among the elite, genetic inequality threatens to mirror, and deepen, existing global divides. UNGENE also examines the unchecked power of biotech giants, the gene patents, and the exploitation of indigenous DNA. With case studies ranging from Africa’s genomic justice initiatives to corporate embryo screening in the U.S., this committee confronts the clash between innovation and accountability. Should there be a global body to regulate human gene editing? Can international norms overcome national interests? The decisions made here will shape not only bodies, but the balance of global power.